Collegium Pharmaceutical, Inc. /
Corium Therapeutics Holdings, LLC
Collegium completes AZSTARYS purchase from Corium units
Source for the buyer and target: COLLEGIUM PHARMACEUTICAL, INC
For the buyer and target.
“As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “ Company ”), entered into an Equity Purchase Agreement (the “ Purchase Agreement ”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“ Commave Seller ”), and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and together with Commave Seller, the “ Seller Parties ”).”
Published 12 May 2026
Open the sourceWhat happened
Collegium Pharmaceutical has finished buying the entities holding the ADHD medicine AZSTARYS from Corium Therapeutics affiliates. The deal was valued at about $650 million in cash, with part of the funding coming from a delayed draw term loan under the credit facility announced in December 2025. [01]
The company says the acquisition strengthens its ADHD portfolio and that it has raised its 2026 financial guidance to reflect the deal. Collegium may also pay up to $135 million more if AZSTARYS hits certain future milestones. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Collegium completes AZSTARYS purchase from Corium units
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Announced
“The deal was valued at about $650 million in cash, with part of the funding coming from a delayed draw term loan under the credit facility announced in December 2025”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly